Literature DB >> 28888058

Increased Expression of Programmed Cell Death-1 in Regulatory T Cells of Patients with Severe Sepsis and Septic Shock: An Observational Clinical Study.

Q Liu1,2, L An1,2, Z Qi1,2, Y Zhao1,2, C Li1,2.   

Abstract

While regulatory T cells (Tregs) constitutively express programmed cell death-1 (PD-1), the role of PD-1 expression in Tregs of patients with sepsis remains unclear. Thus, we determined PD-1 expression in Tregs from the peripheral blood of patients with severe sepsis and septic shock. Seventy-eight patients with severe sepsis and 40 with septic shock, as well as 21 healthy subjects, were enrolled in this study. The percentage of peripheral blood PD-1+ Tregs, as well as absolute Treg counts, were compared between these three groups. PD-1 expression in Tregs and absolute Treg counts were also compared between survivors and non-survivors in patients with sepsis. PD-1 expression in Tregs increased in patients with sepsis compared to healthy controls. Conversely, absolute Treg counts were significantly decreased in patients with sepsis compared to healthy controls; patients with septic shock had the lowest absolute Treg counts. Among patients with sepsis, survivors had lower levels of PD-1 expression in Tregs, as well as higher absolute Treg counts, than non-survivors. Additionally, the percentage of PD-1+ Tregs correlated positively with lactate levels as well as the Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores in patients with sepsis. PD-1 was upregulated in Tregs of patients with sepsis and may indicate a state of immune dysfunction. Overexpression of PD-1 in Tregs was associated with more severe sepsis as well as poor outcomes.
© 2017 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28888058     DOI: 10.1111/sji.12612

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity.

Authors:  Isaac J Jensen; Frances V Sjaastad; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2018-03-01       Impact factor: 5.422

Review 2.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 3.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

Review 4.  Epidemiology and Immune Pathogenesis of Viral Sepsis.

Authors:  Gu-Lung Lin; Joseph P McGinley; Simon B Drysdale; Andrew J Pollard
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

5.  Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions.

Authors:  Adriana Toro; Nunziatina Laura Parrinello; Elena Schembari; Maurizio Mannino; Giuseppe Corsale; Anna Triolo; Filippo Palermo; Alessandra Romano; Francesco Di Raimondo; Isidoro Di Carlo
Journal:  World J Emerg Surg       Date:  2020-03-04       Impact factor: 5.469

6.  Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.

Authors:  Wei-Shuyi Ruan; Meng-Xiao Feng; Jia Xu; Ying-Ge Xu; Cong-Ying Song; Li-Ying Lin; Li Li; Yuan-Qiang Lu
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

Review 7.  The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review.

Authors:  Mutiara Indah Sari; Syafruddin Ilyas
Journal:  Diagnostics (Basel)       Date:  2022-08-19

Review 8.  Novel Diagnostics and Therapeutics in Sepsis.

Authors:  Kieran Leong; Bhavita Gaglani; Ashish K Khanna; Michael T McCurdy
Journal:  Biomedicines       Date:  2021-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.